15.29
price up icon2.62%   0.39
after-market アフターアワーズ: 15.54 0.25 +1.64%
loading
前日終値:
$14.90
開ける:
$15.04
24時間の取引高:
536.94K
Relative Volume:
0.89
時価総額:
$780.84M
収益:
$107.46M
当期純損益:
$105.90M
株価収益率:
7.5409
EPS:
2.0276
ネットキャッシュフロー:
$243.48M
1週間 パフォーマンス:
+10.56%
1か月 パフォーマンス:
-19.78%
6か月 パフォーマンス:
+10.88%
1年 パフォーマンス:
+64.23%
1日の値動き範囲:
Value
$14.95
$15.36
1週間の範囲:
Value
$13.40
$15.36
52週間の値動き範囲:
Value
$7.90
$21.03

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name
名前
Theravance Biopharma Inc
Name
セクター
Healthcare (1114)
Name
電話
650-808-6000
Name
住所
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Name
職員
97
Name
Twitter
Name
次回の収益日
2026-03-25
Name
最新のSEC提出書
Name
TBPH's Discussions on Twitter

Compare TBPH vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
TBPH icon
TBPH
Theravance Biopharma Inc
15.29 760.92M 107.46M 105.90M 243.48M 2.0276
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-05 ダウングレード Oppenheimer Outperform → Perform
2026-03-04 ダウングレード B. Riley Securities Buy → Neutral
2025-12-03 開始されました Oppenheimer Outperform
2025-09-12 開始されました B. Riley Securities Buy
2024-08-06 ダウングレード Leerink Partners Outperform → Market Perform
2024-04-12 開始されました BTIG Research Buy
2024-01-08 ダウングレード Evercore ISI Outperform → In-line
2022-05-23 開始されました SVB Leerink Outperform
2021-11-05 アップグレード JP Morgan Underweight → Neutral
2021-09-15 ダウングレード JP Morgan Overweight → Underweight
2021-08-25 ダウングレード Morgan Stanley Overweight → Underweight
2021-08-24 ダウングレード Cowen Outperform → Market Perform
2020-10-14 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-07-07 開始されました JP Morgan Overweight
2020-06-15 開始されました Morgan Stanley Equal-Weight
2020-05-13 開始されました Cowen Outperform
2020-01-08 繰り返されました H.C. Wainwright Buy
2019-11-06 アップグレード Robert W. Baird Underperform → Neutral
2019-10-29 開始されました H.C. Wainwright Buy
2018-03-29 再開されました Piper Jaffray Overweight
2017-08-17 開始されました Evercore ISI Outperform
2017-06-16 開始されました Cantor Fitzgerald Overweight
2017-05-11 繰り返されました Needham Buy
2016-12-21 開始されました Needham Buy
2016-11-03 開始されました Piper Jaffray Overweight
2016-10-12 ダウングレード Robert W. Baird Neutral → Underperform
2016-08-03 ダウングレード BofA/Merrill Neutral → Underperform
2016-06-20 開始されました Guggenheim Buy
2016-06-20 繰り返されました Leerink Partners Outperform
2016-05-12 開始されました Leerink Partners Outperform
2016-05-05 ダウングレード BofA/Merrill Buy → Neutral
2015-02-03 アップグレード Robert W. Baird Underperform → Neutral
すべてを表示

Theravance Biopharma Inc (TBPH) 最新ニュース

pulisher
Mar 25, 2026

Weiss Asset Management (TBPH) details 7.46M-share, 14.5% Theravance Biopharma stake - Stock Titan

Mar 25, 2026
pulisher
Mar 25, 2026

Theravance drops rare disease drug after late-stage trial setback - MSN

Mar 25, 2026
pulisher
Mar 24, 2026

Theravance's Q4 earnings and revenues miss estimates - MSN

Mar 24, 2026
pulisher
Mar 23, 2026

Theravance Biopharma (NASDAQ:TBPH) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

TBPH: Today's Rating Maintained by TD Cowen with Raised Price Ta - GuruFocus

Mar 23, 2026
pulisher
Mar 23, 2026

TD Cowen raises Theravance Biopharma stock price target on cash flow focus - Investing.com Canada

Mar 23, 2026
pulisher
Mar 23, 2026

Theravance Biopharma 2025 Annual Report: YUPELRI Commercialization, Strategic Review, and Organizational Restructuring - Minichart

Mar 23, 2026
pulisher
Mar 23, 2026

Theravance Biopharma 2025 10-K: $107.5M Revenue, $105.9M Net Income - TradingView

Mar 23, 2026
pulisher
Mar 23, 2026

Theravance Biopharma (NASDAQ: TBPH) restructures after ampreloxetine flop and royalty sale - Stock Titan

Mar 23, 2026
pulisher
Mar 21, 2026

Here's why Theravance Biopharma (TBPH) is a strong growth stock - MSN

Mar 21, 2026
pulisher
Mar 21, 2026

(TBPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Mar 21, 2026
pulisher
Mar 21, 2026

Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research - MarketBeat

Mar 21, 2026
pulisher
Mar 21, 2026

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen - MarketBeat

Mar 21, 2026
pulisher
Mar 20, 2026

Theravance's Q4 Earnings and Revenues Miss Estimates - Yahoo Finance

Mar 20, 2026
pulisher
Mar 20, 2026

BTIG Research Reaffirms "Buy" Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat

Mar 20, 2026
pulisher
Mar 20, 2026

TBPH: BTIG Reiterates Buy Rating with Unchanged Price Target | T - GuruFocus

Mar 20, 2026
pulisher
Mar 19, 2026

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Beats Estimates By $0.71 EPS - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma (TBPH) Profit Swing Reinforces Bullish Narratives Despite Narrow Revenue Base - simplywall.st

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma stock rating reiterated at Buy by BTIG on revenue beat - Investing.com Canada

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma earnings beat by $0.15, revenue fell short of estimates - Investing.com Canada

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma Q4 operating income USD 20.012 million - marketscreener.com

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma 2025 Earnings: Q4 Profit $61M, Revenue Misses EstimatesNews and Statistics - IndexBox

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma (TBPH) Achieves Record Quarter Amidst Strat - GuruFocus

Mar 19, 2026
pulisher
Mar 19, 2026

BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million - TradingView

Mar 19, 2026
pulisher
Mar 19, 2026

TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP - GlobeNewswire

Mar 19, 2026
pulisher
Mar 19, 2026

Ireland's Theravance Biopharma Q4 revenue misses expectations - TradingView

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma reports Q4 2025 net income $61.0M; Q4 revenue $45.9M, cash ~ $400M expected Q1 2026 - TradingView

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Bio: Q4 Earnings Snapshot - kare11.com

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - PR Newswire

Mar 19, 2026
pulisher
Mar 19, 2026

Theravance Biopharma SVP Farnum sells $433k in shares By Investing.com - Investing.com India

Mar 19, 2026
pulisher
Mar 18, 2026

Insider Sell: Rhonda Farnum Sells Shares of Theravance Biopharma Inc (TBPH) - GuruFocus

Mar 18, 2026
pulisher
Mar 18, 2026

Theravance Biopharma SVP Farnum sells $433k in shares - Investing.com

Mar 18, 2026
pulisher
Mar 18, 2026

Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 31,067 Shares - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

Theravance Biopharma (NASDAQ: TBPH) SVP sells 31,067 shares, keeps stake - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Theravance Biopharma (TBPH) price target increased by 28.23% to 27.25 - MSN

Mar 18, 2026
pulisher
Mar 17, 2026

Aug Retail: Why is Theravance Biopharma Inc stock going downGlobal Markets & High Win Rate Trade Tips - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 16, 2026

[144] Theravance Biopharma, Inc. SEC Filing - Stock Titan

Mar 16, 2026
pulisher
Mar 13, 2026

Theravance Biopharma to restructure after late-stage ampreloxetine setback - MSN

Mar 13, 2026
pulisher
Mar 12, 2026

WINTON GROUP Ltd Takes $1.12 Million Position in Theravance Biopharma, Inc. $TBPH - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

Aug Fed Impact: Can Theravance Biopharma Inc sustain its profitabilityQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn

Mar 12, 2026
pulisher
Mar 11, 2026

Once with 360 employees, Theravance Biopharma's latest cuts to whittle workforce to fewer than 50 - The Business Journals

Mar 11, 2026
pulisher
Mar 11, 2026

TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates - PR Newswire

Mar 11, 2026
pulisher
Mar 11, 2026

How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash - Yahoo Finance

Mar 11, 2026
pulisher
Mar 10, 2026

Responsive Playbooks and the TBPH Inflection - Stock Traders Daily

Mar 10, 2026
pulisher
Mar 10, 2026

TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations - TMX Newsfile

Mar 10, 2026
pulisher
Mar 09, 2026

Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) - Finviz

Mar 09, 2026
pulisher
Mar 08, 2026

Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure - Markets Mojo

Mar 08, 2026
pulisher
Mar 07, 2026

Portfolio Recap: Is Theravance Biopharma Inc stock showing strong momentum2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 06, 2026

Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) - Finviz

Mar 06, 2026
pulisher
Mar 06, 2026

HC Wainwright Issues Optimistic Forecast for TBPH Earnings - MarketBeat

Mar 06, 2026

Theravance Biopharma Inc (TBPH) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):